Vast majority of new cancer treatments do not end up improving survival times and generally come with significant, unpleasant side effects. Of the small minori

Vast majority of new cancer treatments do not end up improving survival times and generally come with significant, unpleasant side effects. Of the small minority that are found to be a net benefit, most are just barely worth it: very modest extension of life expectancy with sufficient toxicity that many well-informed patients will nevertheless decline them. This is not just chemo either; immunotherapies can be brutal.